clinical trial data

Abivax CEO dismisses acquisition rumors, plans equity and debt raise after Phase 3 obefazimod data in Q2 2026. $614.42M cash runway supports strategy.

Novartis presents 20+ abstracts at AAD 2026, highlighting rapid symptom relief with Rhapsido and long-term efficacy data for Cosentyx across multiple skin conditions.

Apogee Therapeutics to present 52-week Phase 2 data for APG777 in atopic dermatitis on March 23, 2026, signaling major clinical development milestone.

Soleno Therapeutics faces securities lawsuit after hyperphagia drug VYKAT XR launch falters amid safety concerns, driving shares down 40% since August short seller report.

Chinese biotech Jacobio Pharmaceuticals expects profitability in 2026 via $100M AstraZeneca deal for KRAS inhibitor and growing Glecirasib sales.

XOMA Royalty reports $50M+ cash receipts in 2025, with royalties up 68% YoY. Company adds 22 assets, completes seven acquisitions, and repurchases $16M in shares.

Securities class action filed against $SLNO alleging false statements about DCCR drug safety. Investors must claim lead plaintiff status by May 5, 2026.

GSK's Arexvy RSV vaccine gains FDA approval for younger high-risk adults aged 18-49, expanding market beyond 60+ population on strong Phase 3b data and £198M Q4 sales.

Class action lawsuit filed against $VTGN alleges securities fraud over misleading statements about fasedienol drug candidate and PALISADE-3 clinical trial data.

Rhythm Pharmaceuticals reports positive Phase 3 data for setmelanotide treating acquired hypothalamic obesity, with FDA decision expected March 2026.

Class action lawsuit filed against Vistagen Therapeutics for alleged false statements regarding drug trial data. Investors who purchased securities April 2024-December 2025 may be eligible.

Staar Surgical wins FDA approval to expand implantable lens eligibility to patients aged 21-60, up from 21-45, potentially reaching 8 million additional U.S. candidates.